JP4357001B2 - 中枢神経系障害の予防及び治療のための医薬組成物 - Google Patents

中枢神経系障害の予防及び治療のための医薬組成物 Download PDF

Info

Publication number
JP4357001B2
JP4357001B2 JP53818097A JP53818097A JP4357001B2 JP 4357001 B2 JP4357001 B2 JP 4357001B2 JP 53818097 A JP53818097 A JP 53818097A JP 53818097 A JP53818097 A JP 53818097A JP 4357001 B2 JP4357001 B2 JP 4357001B2
Authority
JP
Japan
Prior art keywords
methyl
amine
pyridinyl
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53818097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000509041A5 (enExample
JP2000509041A (ja
Inventor
コールドウェル，ウィリアム・スコット
ダル，ゲイリー・モーリス
ドブソン，グレイランド・ペイジ
Original Assignee
ターガセプト，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24532629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4357001(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ターガセプト，インコーポレイテッド filed Critical ターガセプト，インコーポレイテッド
Publication of JP2000509041A publication Critical patent/JP2000509041A/ja
Publication of JP2000509041A5 publication Critical patent/JP2000509041A5/ja
Application granted granted Critical
Publication of JP4357001B2 publication Critical patent/JP4357001B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP53818097A 1996-04-23 1997-04-16 中枢神経系障害の予防及び治療のための医薬組成物 Expired - Fee Related JP4357001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63176196A 1996-04-23 1996-04-23
US08/631,761 1996-04-23
PCT/US1997/006398 WO1997040011A1 (en) 1996-04-23 1997-04-16 Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008060649A Division JP2008247903A (ja) 1996-04-23 2008-03-11 中枢神経系障害の予防及び治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2000509041A JP2000509041A (ja) 2000-07-18
JP2000509041A5 JP2000509041A5 (enExample) 2005-12-08
JP4357001B2 true JP4357001B2 (ja) 2009-11-04

Family

ID=24532629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53818097A Expired - Fee Related JP4357001B2 (ja) 1996-04-23 1997-04-16 中枢神経系障害の予防及び治療のための医薬組成物
JP2008060649A Pending JP2008247903A (ja) 1996-04-23 2008-03-11 中枢神経系障害の予防及び治療のための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008060649A Pending JP2008247903A (ja) 1996-04-23 2008-03-11 中枢神経系障害の予防及び治療のための医薬組成物

Country Status (12)

Country Link
US (2) US6603011B1 (enExample)
EP (2) EP0900200B9 (enExample)
JP (2) JP4357001B2 (enExample)
AT (1) ATE416164T1 (enExample)
AU (1) AU727976B2 (enExample)
BR (1) BR9708815B1 (enExample)
CA (1) CA2252515C (enExample)
DE (1) DE69739142D1 (enExample)
DK (1) DK0900200T5 (enExample)
ES (1) ES2318856T4 (enExample)
PT (1) PT900200E (enExample)
WO (1) WO1997040011A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
AU2880699A (en) 1998-04-02 1999-10-25 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
US20050131034A1 (en) 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
EP1086082B9 (en) * 1998-06-16 2005-03-02 Targacept, Inc. Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
AU2005201609B2 (en) * 1999-04-20 2007-10-18 Targacept, Inc Pharmaceutical compositions for inhibition of cytokine production and secretion
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
EP1185514A1 (en) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
NZ516888A (en) * 1999-07-30 2004-02-27 Vertex Pharma Acyclic and cyclic amine derivatives
WO2001082978A2 (en) * 2000-05-01 2001-11-08 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
AU2003258754A1 (en) * 2002-04-16 2003-11-11 Rhodia Chimie Aminated compounds bearing at least an allyl and a difluoromethyl and method used for synthesis thereof
FR2838436A1 (fr) * 2002-04-16 2003-10-17 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
FR2847578A1 (fr) * 2002-11-21 2004-05-28 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
ATE442822T1 (de) * 2004-04-02 2009-10-15 Arterial Remodelling Technolog Stentanordnung auf polymerbasis
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2357174A1 (en) 2006-05-09 2011-08-17 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
EP2647373A1 (en) 2008-05-12 2013-10-09 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine.
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8703802B2 (en) 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4684654A (en) * 1985-08-14 1987-08-04 American Cyanamid Company 3-heteroalkyl-2,4-quinzaolinediones
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4786646A (en) * 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
DE4102289A1 (de) 1991-01-26 1992-07-30 Bayer Ag Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
JP3153551B2 (ja) 1991-05-29 2001-04-09 アボツト・ラボラトリーズ 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
AU4610896A (en) * 1995-01-06 1996-07-24 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds

Also Published As

Publication number Publication date
DE69739142D1 (de) 2009-01-15
EP1997806A1 (en) 2008-12-03
AU2733297A (en) 1997-11-12
CA2252515C (en) 2006-11-07
EP0900200A1 (en) 1999-03-10
EP0900200B9 (en) 2009-10-21
JP2000509041A (ja) 2000-07-18
DK0900200T5 (da) 2010-01-11
ES2318856T3 (es) 2009-05-01
BR9708815A (pt) 2000-01-04
US6603011B1 (en) 2003-08-05
DK0900200T3 (da) 2009-03-30
EP0900200B1 (en) 2008-12-03
US6555684B2 (en) 2003-04-29
ATE416164T1 (de) 2008-12-15
CA2252515A1 (en) 1997-10-30
WO1997040011A1 (en) 1997-10-30
AU727976B2 (en) 2001-01-04
US20020032206A1 (en) 2002-03-14
ES2318856T4 (es) 2010-03-03
BR9708815B1 (pt) 2009-01-13
PT900200E (pt) 2009-02-26
JP2008247903A (ja) 2008-10-16

Similar Documents

Publication Publication Date Title
JP4357001B2 (ja) 中枢神経系障害の予防及び治療のための医薬組成物
US5616716A (en) (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5726316A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5597919A (en) Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5861423A (en) Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5824692A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5731314A (en) Pharamceutical compositions for prevention and treatment of tourette's syndrome
EP0801527B1 (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US7045538B2 (en) Compounds capable of activating cholinergic receptors
KR100572189B1 (ko) 아릴 치환된 올레핀계 아민 화합물을 혼합한 약학 조성물
US6531606B1 (en) Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US7060826B2 (en) Compounds capable of activating cholinergic receptors
KR100568997B1 (ko) 중추신경계질환의예방및치료를위한약제학적조성물
HK1126213A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
MXPA00012858A (en) Aryl substituted olefinic amines and their use as cholinergic receptors agonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040127

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080311

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080311

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090721

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090804

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120814

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130814

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees